Effects of an anti-IL-36R antibody treatment were investigated either after establishment of IMQ-induced psoriasis or in keratinocyte-specific IL-17A overexpressing mice (K14-IL17Aind mice), harboring a heterogeneous deletion of the psoriasis-promoting factor IκBζ (Nfkbiz). The gene discussed is IL1RL2; the disease is psoriasis.